TREH Biomarker Data for Clear Cell Renal Cell Carcinoma Prognosis

A 215.6 KB document presents findings from an integrated transcriptomic analysis of clear cell renal cell carcinoma. The study, authored by Kuo Ma and last updated in May 2026, identified Trehalase (TREH) as a novel protective biomarker and prognostic predictor using TCGA-KIRC cohort data, machine learning, and single-cell RNA-seq validation.

Use Cases

• Building prognostic models for ccRCC based on TREH expression and clinical parameters.
• Analyzing tumor microenvironment crosstalk based on VEGF, PLG, and APP signaling pathways.
• Investigating the link between epithelial cell gene expression and EMT promotion in ccRCC.
• Validating single-cell RNA-seq findings with in vitro and in vivo assay data.

Strengths

• Integrated analysis combines bulk RNA-seq (TCGA-KIRC), single-cell RNA-seq, and experimental validation.
• Prognostic model was developed with a 70/30 train-test split and validated internally.
• Findings are supported by in vitro and in vivo assays demonstrating TREH's tumor-suppressive role.

Limitations

• The primary data file is a 215.6 KB DOCX document, not a structured dataset; data extraction is required.
• Column-level documentation and sample data are unavailable, limiting immediate usability.
• Row count and specific data tables are unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Integrated transcriptomic data analysis combining WGCNA, machine learning (LASSO, GBM), and scRNA-seq.

Freshness

Last updated 2026-05-11 04:26:38